Home > Expanded Access > ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Eli Lilly and Company

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Brief Summary: 
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Approved for marketing
Mesothelioma

Drug: Pemetrexed

Drug: Cisplatin

Eligibility Criteria: 

Inclusion Criteria:

- Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery

- Prior chemotherapy for your disease is allowed

- Measurable lesion is not required

- Have a adequate performance status

- Sign an informed consent form

Exclusion Criteria:

- You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study

- You are excluded from this trial if you have received radiation within the previous 2 weeks

- You are excluded from this trial if you are a candidates for curative surgery

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 18 Years
Countries: 
Brazil, Egypt, Saudi Arabia, United States
Locations: 

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Basking Ridge, New Jersey,

Eli Lilly and Company
EA Number: 
MeSH Terms: 
Mesothelioma, Cisplatin, Pemetrexed
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.